Executives
-
O'Sullivan MiriamSVP, Chief HR Officer -
Sorenson John BradleyEVP, Global Operations
-
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
-
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
-
Brown Vance RSVP, GC and Corp. Secretary
-
Brennan Daniel J.EVP and CFO
-
Carruthers WendyEVP, Human Resources
-
Woodworth EmilySVP, Global Controller and CAO
-
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
-
Monson JonathanSVP, Global Controller and CAO
?
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
Boston Scientific Corporation
US, Marlborough [HQ]
CIK
1484186
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
2,353,760,000
Price per Share :
$98.66
Equivalence :
$232,221,961,600.00
Transaction History
-
M2,353,760,000 Shares After TransactionValue : $40,625,897,600.00$10,187,024,600.00Transaction Date : 10/07/24
-
Footnotes
-
-
Footnotes:#1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024.#2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.01, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
-
M2,929,940,000 Shares After TransactionValue : $73,189,901,200.00$14,392,976,400.00Transaction Date : 10/07/24
-
Footnotes
-
-
Footnotes:#1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024.#2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.01, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
-
S1,604,670,000 Shares After TransactionValue : $136,396,950,000.00Sold $112,647,950,000.00Transaction Date : 10/07/24
-
Footnotes
-
-
Footnotes:#1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024.#2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.01, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
-
M1,906,860,000 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/16/24
-
Footnotes
-
-
Footnotes:#1 Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.#2 Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.
-
F1,888,800,000 Shares After TransactionValue : $124,320,816,000.00$1,188,709,200.00Transaction Date : 02/16/24
-
Footnotes
-
-
Footnotes:#1 Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.#2 Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.